2026-07-06T14:41:17Z https://datacatalogue.cessda.eu/oai-pmh/v0/oai

9150382e6acdbb3e3397209722b6d410bf6a28bcc3e6563b97a8f8b7a70259bf 2026-06-02T14:15:33Z language:svopenaire_data

Data for: Prevalence of protective tetanus antibodies and immunological response following tetanus toxoid vaccination among men seeking medical circumcision services in Uganda Swedish National Data ServiceSvensk nationell datatjänst Landing page Data for: Prevalence of protective tetanus antibodies and immunological response following tetanus toxoid vaccination among men seeking medical circumcision services in Uganda Data for: Prevalence of protective tetanus antibodies and immunological response following tetanus toxoid vaccination among men seeking medical circumcision services in Uganda snd1065-1-1.0https://doi.org/10.5878/2vmc-5511 Makumbi, Fredrick Makumbi, Fredrick Swedish National Data ServiceSvensk nationell datatjänst 2019-01-14 Landing page Tetanus ToxoidStelkrampsvaccinToxoidsToxoiderVaccinesVaccinerBiological ProductsBiologiska produkterComplex MixturesKomplexa blandningar Medical and Health SciencesMedicin och hälsovetenskapHEALTHHÄLSA Introduction: Tetanus infection associated with men who had male circumcision has been reported in East Africa, suggesting a need for tetanus toxoid-containing vaccines (TTCV). Objective: To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision. Methods: We enrolled 620 consenting men who completed a questionnaire and received TTCV at enrollment (day 0) prior to circumcision on day 28. Blood samples were obtained at day 0 from all enrollees and on days 14, 28 and 42 from a random sample of 237 participants. Tetanus toxoid (TT) IgG antibody levels were assayed using EUROIMMUN. Analyses included prevalence of TT antibodies at enrollment and used a mixed effects model to determine the immunological response. Results: Mean age was 21.4 years, 65.2% had knowledge of tetanus, 56.6% knew how tetanus was contracted, 22.8% reported ever receipt of TTCV, and 16.8% had current/recently healed wounds. Insufficient tetanus immunity was 57.1% at enrollment, 7.2% at day 14, 3.8% at day 28, and 0% at day 42. Antibody concentration was 0.44IU/ml (CI 0.35-0.53) on day 0, 3.86IU/ml (CI 3.60-4.11) on day 14, 4.05IU/ml (CI 3.81-4.29) on day 28, and 4.48IU/ml (CI 4.28-4.68) on day 42. TT antibodies increased by 0.24IU/ml (CI 0.23, 0.26) between days 0 and 14 and by 0.023IU/ml (CI 0.015, 0.031) between days 14 and 42 days. Immunological response was poorer in HIV-infected clients and men aged 35+ years. Conclusion: Insufficient immunity was common prior to TTCV, and a protective immunological response was achieved by day 14. Circumcision may safely be provided 14 days after vaccination in HIV-uninfected men aged less than 35 years. Purpose: To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision. Observations: 1,217 variables: 14 size: 116,832 Social demographics, TT antibody concentration, interpretation of concentration, participant identification variableIntroduction: Tetanus infection associated with men who had male circumcision has been reported in East Africa, suggesting a need for tetanus toxoid-containing vaccines (TTCV). Objective: To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision. Methods: We enrolled 620 consenting men who completed a questionnaire and received TTCV at enrollment (day 0) prior to circumcision on day 28. Blood samples were obtained at day 0 from all enrollees and on days 14, 28 and 42 from a random sample of 237 participants. Tetanus toxoid (TT) IgG antibody levels were assayed using EUROIMMUN. Analyses included prevalence of TT antibodies at enrollment and used a mixed effects model to determine the immunological response. Results: Mean age was 21.4 years, 65.2% had knowledge of tetanus, 56.6% knew how tetanus was contracted, 22.8% reported ever receipt of TTCV, and 16.8% had current/recently healed wounds. Insufficient tetanus immunity was 57.1% at enrollment, 7.2% at day 14, 3.8% at day 28, and 0% at day 42. Antibody concentration was 0.44IU/ml (CI 0.35-0.53) on day 0, 3.86IU/ml (CI 3.60-4.11) on day 14, 4.05IU/ml (CI 3.81-4.29) on day 28, and 4.48IU/ml (CI 4.28-4.68) on day 42. TT antibodies increased by 0.24IU/ml (CI 0.23, 0.26) between days 0 and 14 and by 0.023IU/ml (CI 0.015, 0.031) between days 14 and 42 days. Immunological response was poorer in HIV-infected clients and men aged 35+ years. Conclusion: Insufficient immunity was common prior to TTCV, and a protective immunological response was achieved by day 14. Circumcision may safely be provided 14 days after vaccination in HIV-uninfected men aged less than 35 years. Syfte: To determine the prevalence of tetanus toxoid antibodies following vaccination among men seeking circumcision. Observations: 1,217 variables: 14 size: 116,832 Social demographics, TT antibody concentration, interpretation of concentration, participant identification variable 2016-01-102016-11-022016-01-102016-11-02 UgandaUganda InterviewIntervjuMeasurements and testsMätningar och tester Access to data through SND. Access to data is restricted.Åtkomst till data via SND. Tillgång till data är begränsad. https://snd.gu.se snd1065-1 2023-05-22T11:59:57Z ddi:codebook:2_5